A Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) as Monotherapy and in Combination with Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Trial Identifier:	2870-011
Sponsor:	MSD
Start Date:	March 2025
Primary Completion Date:	May 2030
Study Completion Date:	May 2030
Condition:	Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	Protocol Plain Language Summary

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

No locations posted.

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.